Nivolumab
bms
['lymsm', 'nivolumab', 'opal', 'lymphoma', 'nivo']
#eha2022 | , , presented an interim analysis of the phase ii aern trial, showing nivolumab and 20gy rt at a single lesion was well tolerated and led to an abscopal response in 56% of pts previously failing anti-pd1 treatment for r/r hl #lymsm #lymphoma 
A global education platform providing clinical updates on a range of lymphoma subtypes and chronic lymphocytic leukemia (#CLL) #lymsm